RECRUITING

Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts

Description

The DART-HA study is a single-center, open label, trial intended to evaluate the clinical efficacy of standard treatment options for congestive heart failure (observation, diuretic or afterload reduction therapy) in patients without new symptoms who have developed abnormalities of the HeartLogic heart failure diagnostic feature.

Conditions

Heart Failure, Congestive
Talk to us

Related Conditions:

Heart Failure, Congestive

Study Overview

On this page

Study Details

Study overview

The DART-HA study is a single-center, open label, trial intended to evaluate the clinical efficacy of standard treatment options for congestive heart failure (observation, diuretic or afterload reduction therapy) in patients without new symptoms who have developed abnormalities of the HeartLogic heart failure diagnostic feature.

Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts (DART-HA)

Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts

Condition
Heart Failure, Congestive
Intervention / Treatment

-

Contacts and Locations

Huntsville

Heart Center Research, LLC, Huntsville, Alabama, United States, 35801

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Boston Scientific device with HeartLogic enabled
  • * Lack of standard contraindications to Sacubitril/valsartan:
  • * history of ACE-inhibitor induced angioedema and in those with angiotensin II receptor blocker (ARB) therapy induced angioedema.
  • * hypotension, hypovolemia
  • * renal artery stenosis, renal failure
  • * hyperkalemia
  • * hepatic disease Child-Pugh class C
  • * Pregnancy/Breast-feeding
  • * Lack of standard contraindications to diuretic therapy
  • * Systolic Blood Pressure \> 105
  • * Glomerular filtration rate \<25 mL/min who are non-responsive to diuretic therapy or are on chronic renal dialysis
  • * ongoing symptoms of heart failure decompensation (increased dyspnea and/or fatigue, for purposes of this study increased weight is not considered, see question 2 KCCQ).
  • * recent significant change in arrhythmia burden (within the past 2 weeks)
  • * in cardiac resynchronization therapy (CRT) patients, recent change (60 days) in effective delivery of CRT (eg. decreased biventricular paving %)
  • * the subject is unable to sign or refuses to sign the patient informed consent
  • * Symptomatic heart failure at rest or New York Heart Association Class IV at the time of enrollment
  • * the subject is implanted with unipolar right atrial or right ventricular leads
  • * subject has received or is scheduled to receive a heart transplant or ventricular assist device within the next 6 months
  • * subject is pregnant or planning to become pregnant during the study
  • * regularly scheduled IV heart failure therapy (e.g. inotropes or diuretics)

Ages Eligible for Study

19 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Heart Center Research, LLC,

Jay Dinerman, MD, PRINCIPAL_INVESTIGATOR, Heart Center Research, LLC

Study Record Dates

2026-12-31